Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net loss			$ (7,171,529)	$ (6,280,143)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			10,857	11,461
Stockbased compensation			255,363	214,318
Foreign currency loss (gain)	$ 29,124	$ 5,502	80,927	(50,674)
Changes in operating assets and liabilities:
Prepaid expenses and other current and noncurrent assets			347,749	(223,296)
Accounts payable			(161,605)	(703,473)
Accrued expenses			(123,679)	(67,470)
Deferred grant revenue				(478,235)
Net cash used in operating activities			(6,761,917)	(7,577,512)
Cash flows from investing activities:
Purchases of property and equipment				(15,478)
Net cash used in investing activities				(15,478)
Cash flows from financing activities:
Proceeds from issuance of common stock			459,019	15,999,598
Common stock issuance costs			(18,291)	(1,310,953)
Net cash provided by financing activities			440,728	14,688,645
Change in cash, cash equivalents and restricted cash			(6,321,189)	7,095,655
Effect of exchange rate changes on cash, cash equivalents and restricted cash			4,006	(7,238)
Cash, cash equivalents and restricted cash-beginning of year			22,890,055	21,647,537	$ 21,647,537
Cash, cash equivalents and restricted cash-end of period	16,572,872	28,735,954	16,572,872	28,735,954	22,890,055
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	16,532,199	28,694,694	16,532,199	28,694,694	22,849,885
Restricted cash	40,673	41,260	40,673	41,260	40,170
Total cash, cash equivalents and restricted cash	$ 16,572,872	$ 28,735,954	16,572,872	$ 28,735,954	$ 22,890,055
Non-cash investing and financing activities:
Conversion of Series A convertible preferred stock to common stock			$ 583,702